CL2018003076A1 - Formulaciones con sistemas lípidos portadores de compuestos bioactivos para uso como agentes adyuvante o potenciador de la terapia inmunológica en pacientes que sufren de cáncer o trastornos inmunológicos. - Google Patents

Formulaciones con sistemas lípidos portadores de compuestos bioactivos para uso como agentes adyuvante o potenciador de la terapia inmunológica en pacientes que sufren de cáncer o trastornos inmunológicos.

Info

Publication number
CL2018003076A1
CL2018003076A1 CL2018003076A CL2018003076A CL2018003076A1 CL 2018003076 A1 CL2018003076 A1 CL 2018003076A1 CL 2018003076 A CL2018003076 A CL 2018003076A CL 2018003076 A CL2018003076 A CL 2018003076A CL 2018003076 A1 CL2018003076 A1 CL 2018003076A1
Authority
CL
Chile
Prior art keywords
bioactive compounds
immune
formulations
enhancer
cancer
Prior art date
Application number
CL2018003076A
Other languages
English (en)
Inventor
Olivares Carlos Torres
De Frutos Luis Vásquez
Marta Corzo
Pablo Arranz
De Molina Ana Ramírez
Rada Guillermo Reglero
Kohen Viviana Loria
De Cedrón Marta Gómez
Rubio Juan Moreno
Llopis Moisés Laparra
Sáenz Enrique Casado
Original Assignee
Univ Madrid Autonoma
Imdea Alimentacion
Hospital Univ Infanta Sofia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Madrid Autonoma, Imdea Alimentacion, Hospital Univ Infanta Sofia filed Critical Univ Madrid Autonoma
Publication of CL2018003076A1 publication Critical patent/CL2018003076A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN SISTEMA LIPÍDICO QUE NO SÓLO MEJORA LA ESTABILIDAD DURANTE LA DIGESTIÓN Y BIODISPONIBILIDAD ORAL DE FORMA SEGURA Y EFICAZ DE DIVERSOS COMPUESTOS BÍOACTIVOS SINO QUE EN MUCHOS CASOS POTENCIA LOS EFECTOS DE DICHOS COMPUESTOS. ASIMISMO, LA PRESENTE INVENCIÓN PROPORCIONA FORMULACIONES O COMPOSICIONES QUE COMPRENDEN SISTEMAS LÍPIDOS PORTADORES DE COMPUESTOS BIOACTIVOS PARA SU USO COMO AGENTES ADYUVANTES O POTENCIADORES DE LA TERAPIA INMUNOLÓGICA EN PACIENTES QUE SUFREN DE CÁNCER O DE TRASTORNOS INMUNOLÓGICOS.
CL2018003076A 2016-04-29 2018-10-29 Formulaciones con sistemas lípidos portadores de compuestos bioactivos para uso como agentes adyuvante o potenciador de la terapia inmunológica en pacientes que sufren de cáncer o trastornos inmunológicos. CL2018003076A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201630560 2016-04-29

Publications (1)

Publication Number Publication Date
CL2018003076A1 true CL2018003076A1 (es) 2019-05-17

Family

ID=60161236

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003076A CL2018003076A1 (es) 2016-04-29 2018-10-29 Formulaciones con sistemas lípidos portadores de compuestos bioactivos para uso como agentes adyuvante o potenciador de la terapia inmunológica en pacientes que sufren de cáncer o trastornos inmunológicos.

Country Status (11)

Country Link
US (2) US11478008B2 (es)
EP (2) EP3679940A1 (es)
JP (1) JP2019516786A (es)
KR (1) KR20190003689A (es)
CN (1) CN109843312A (es)
BR (1) BR112018072087A2 (es)
CA (1) CA3022501A1 (es)
CL (1) CL2018003076A1 (es)
ES (1) ES2898527T3 (es)
RU (2) RU2021104805A (es)
WO (1) WO2017187000A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016396401B2 (en) 2016-03-07 2023-07-13 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject
BR112023005326A2 (pt) * 2020-09-24 2023-04-25 Mars Inc Composições alimentares e suas aplicações

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE347433B (es) * 1966-12-16 1972-08-07 Astra Nutrition Ab
DE3131524A1 (de) 1981-08-08 1983-02-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung physiologischer effektoren
CN1327038A (zh) * 2001-07-18 2001-12-19 孙传经 超临界co2反向萃取法提取迷迭香抗氧化剂的方法
US7067159B2 (en) 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
PT104158B (pt) 2008-08-18 2011-02-24 Univ Do Minho Aplicação da monooleína como novo lípido adjuvante em lipofecção
FR2945951B1 (fr) * 2009-05-26 2012-07-13 Polaris Composition d'akg et son utilisation pour la fabrication d'un medicament.
CA2763041C (en) * 2009-05-29 2018-11-27 Robert A. Newman Compositions and methods for modulating lipid composition
US20120082720A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
WO2012161294A1 (en) * 2011-05-20 2012-11-29 Kao Corporation Oil or fat compositions containing diglycerides
ES2408730B1 (es) * 2011-10-27 2014-04-28 Universidad Autónoma de Madrid Composiciones de extracto de romero para el tratamiento de cáncer
CN105030678A (zh) * 2015-08-10 2015-11-11 江苏大学 一种高稳定性的迷迭香精油纳米脂质体抗菌剂及制备方法

Also Published As

Publication number Publication date
US11478008B2 (en) 2022-10-25
KR20190003689A (ko) 2019-01-09
CN109843312A (zh) 2019-06-04
EP3453399A4 (en) 2019-12-25
EP3453399B1 (en) 2021-06-30
EP3453399A1 (en) 2019-03-13
ES2898527T3 (es) 2022-03-07
EP3679940A1 (en) 2020-07-15
BR112018072087A2 (pt) 2019-02-19
WO2017187000A1 (es) 2017-11-02
CA3022501A1 (en) 2017-11-02
RU2018141858A3 (es) 2020-06-30
JP2019516786A (ja) 2019-06-20
US20190037900A1 (en) 2019-02-07
RU2021104805A (ru) 2021-03-23
US20230146568A1 (en) 2023-05-11
RU2018141858A (ru) 2020-05-29

Similar Documents

Publication Publication Date Title
CL2018001845A1 (es) Moduladores de la 5'-nucleotidasa, ecto y su uso
MX2019007156A (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
MX2017007169A (es) Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
JO3606B1 (ar) معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
MX378273B (es) Compuestos activos hacia bromodominios.
MX2016007658A (es) Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevencion de enfermedades aumentando el nivel de colesterol hdl.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
IL290130A (en) Treatment of immune evasive tumors
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
CR20150426A (es) 2,3-benzodiazepinas biciclo y espirocíclico sustituidas
MX2018001756A (es) Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2019003293A1 (es) Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para su uso en el tratamiento de tumores sólidos.
MX384447B (es) Composiciones farmacéuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
HK1219896A1 (zh) 使用4-氨基-2-(2，6-二氧代-呱啶-3-基)-异吲哚啉-1，3-二酮治疗和控制中枢神经系统癌症的方法和组合物
CL2018003076A1 (es) Formulaciones con sistemas lípidos portadores de compuestos bioactivos para uso como agentes adyuvante o potenciador de la terapia inmunológica en pacientes que sufren de cáncer o trastornos inmunológicos.
MA50862A (fr) Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη